Connect with us

Press Releases

ABB Optical Group Announces Leadership Changes

6 people have taken new positions.

mm

Published

on

(PRESS RELEASE) CORAL SPRINGS, FL – ABB Optical Group announced changes to its leadership team and an addition to its board of directors.

“ABB Optical is evolving, and with our new organizational structure in place, we are better positioned to deftly navigate market changes and strategically focus on the future success of our customers,” said ABB Optical Group CEO Tom Burke. “Each of these leaders brings experience, knowledge and passion to our team. I look forward to working closely with each to them as we bring our strategic vision to life and champion the customer at every turn.”

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

Meghan (Meg) FitzGerald
Meg FitzGerald has joined the ABB Optical Group board of directors. FitzGerald serves as managing partner of L1 Health. With $3 billion of capital under management, L1 Health is focused on long-term value creation as the healthcare investment vehicle of LetterOne, an international investment business. Prior to L1 Health, FitzGerald was executive vice president of strategy, mergers and acquisitions and health policy at Cardinal Health and a member of the company’s executive committee. She also is a member of the board of directors for SeniorLink, an innovative proven model of in-home care for elders; Concert Pharmaceuticals, a clinical stage biopharmaceutical company; Gelesis, a biotechnology company developing a novel category of potential therapies for obesity; Tenet Healthcare, a leading Fortune 200 healthcare service company; and Arix Bioscience, a public global healthcare and life sciences specialist company supporting medical innovation. Additionally, FitzGerald serves as an assistant professor at Columbia University in New York, where she teaches the business of healthcare and strategy.

Mike Bono
Mike Bono has been named ABB Optical Group’s new chief financial officer and will oversee the administrative, financial and risk management operations of the company. Bono has more than 30 years of financial management experience with public and private companies. Prior to joining ABB Optical, he was the chief financial officer of Medical Specialties Distributors, a leading post-acute service solutions provider serving the home infusion, home medical equipment and oncology markets.

Michael Dell, Esq.
Attorney Michael Dell has been appointed as ABB Optical Group’s general counsel, a newly created position. Dell will be responsible for leading strategic and tactical legal initiatives, providing the senior management team with effective advice on company strategies and their implementation and securing and overseeing the work of outside counsel as needed. He has more than 20 years of legal experience as an attorney and general counsel. Dell also joins ABB Optical Group from Medical Specialties Distributors, where he served as general counsel.

Erika Jurrens
Erika Jurrens has joined ABB Optical Group as senior vice president of strategic development and commercialization. Jurrens will oversee strategy and execution of products, programs and services with a close eye on how each area of the business benefits customers and patients. Previously, Jurrens led product development and marketing as vice president for Cardinal Health, a Fortune 15 company with revenues topping $100 billion.

Advertisement

Aaron See
Previously vice president of marketing, Aaron See is now senior vice president of manufacturer partnerships, a newly created position. See will be responsible for all aspects of ABB Optical Group’s vendor strategies, leading and enhancing a centralized vendor management function to develop strategic vendor partnerships, implement programs and improve processes. The 20-year industry veteran also will oversee ABB OPTICAL’s gas permeable and custom soft lenses business. Prior to joining ABB OPTICAL in 2014, See was vice president of marketing at Johnson & Johnson’s Vision Care division in Japan.

Paul Sherman
Paul Sherman has taken a new position as chief development officer. He previously led ABB Optical Group’s finance team for eight years as chief financial officer. In his new role, Sherman will be responsible for business development, acquisitions and execution of the company’s prioritized opportunities. Sherman has more than 30 years of finance and accounting experience and has held leadership positions in public, private and private-equity owned companies. Prior to joining ABB OPTICAL, he served as chief financial officer of LNR Property Corporation, a $4 billion diversified real estate investment, finance, management and development company.

Advertisement

SPONSORED VIDEO

SPONSORED BY REICHERT

When You’re Passionate About Eye Care, the Right Technology Matters

Lisa Genovese, O.D., strives to give her patients the very best. At Insight Eye Care’s multiple locations, Dr. Genovese provides optimal care for her patients using the Reichert® Phoroptor® VRx Digital Refraction System. In this second Practice Profile Video from Reichert’s “Passionate About Eye Care” series, take a closer look and see how this eye care professional achieved a better work-life balance with equipment that’s designed and engineered in the U.S.A.

Promoted Headlines

Press Releases

CooperVision Names Senior Brand Marketing Director for Myopia Management in North America

She has more than 20 years of professional experience in the healthcare space.

mm

Published

on

Jane Agbontaen

(PRESS RELEASE) SAN RAMON, CA — CooperVision has named Jane Agbontaen as senior brand director for Myopia Management – Americas. In this newly created role, Agbontaen will be responsible for the strategic planning and execution of all activities that support the U.S. growth of CooperVision’s myopia management portfolio, specifically the Brilliant Futures Myopia Management Program with MiSight 1 day, the first and only FDA-approved product1 clinically proven to slow the progression of myopia when initially prescribed for children 8-12 years old in the U.S.

Agbontaen’s role includes cross-functional and cross-business support to ensure CooperVision’s MiSight 1 day commercialization strategy is successful. Growing the portfolio includes touchpoints with eyecare practitioners and patients, as well as healthcare and legislative ecosystems that govern children’s health and wellness.

“With the FDA approval of MiSight and the impending roll out of our Brilliant Futures Myopia Management Program, we require an evolution of our sales and marketing approach as we take on the rising epidemic of childhood myopia. Going forward, broadening our scope of healthcare provider alliances and industry partnerships are essential elements of shaping the standard of care in myopia management,” said Simon Seshadri, vice president of marketing at CooperVision, North America. “Jane’s previous experiences and skills are a perfect fit for this role and to help us achieve our desired outcomes. I’m delighted to have her onboard.”

Agbontaen has more than 20 years of professional experience in the healthcare space and with large medical device players such as Hologic, Abbot Medical Optics and Johnson & Johnson DePuy Synthes. While at Abbot Medical Optics, which was acquired by Johnson & Johnson Vision Care during her tenure, Agbontaen managed a broad brand portfolio in the cataracts segment, including intraocular lenses and instruments. Agbontaen received her bachelor’s degree from Long Island University and her MBA from the Stern School at New York University.

Continue Reading

Press Releases

OGI Eyewear Names Chief Creative Officer

He will not only lead creative development but will also serve as partner.

mm

Published

on

(PRESS RELEASE) OGI Eyewear, a member of The Optical Foundry, announces the appointment of David Duralde as chief creative officer. Duralde has joined the company not only to lead creative development but also as a partner.

Duralde’s distinguished optical career is marked by extensive experience both with licensed and independent brands, including his most recent role as Chief Creative Officer at Kenmark Eyewear. “I am very excited about the opportunity to redefine and reinvigorate the niche independent brands in the OGI portfolio of products and provide a consistent, compelling story to the brands. I can’t wait to get started with the OGI
Eyewear product and marketing teams to connect deeply with our loyal customers, create frames that light up many more faces and help independent practices thrive and shine in this vigorously changing market.” said Duralde.

Robert Rich, CEO of OGI, notes, “David is exactly the right person to lead us in the revitalization of our brand portfolio. Despite a solid market position, OGI and its family of brands will benefit from an injection of fresh ideas and design innovations that will expand our leading role in the realm of affordable luxury frames.”

Rich adds, “This is a homecoming of sorts for David, having begun his formative optical design training at l.a.Eyeworks, another member of the Optical Foundry.”

Continue Reading

Press Releases

First US Patient Gets Wireless Retinal Device Implant

It’s aimed at restoring partial sight to patients with advanced age-related macular degeneration.

mm

Published

on

(PRESS RELEASE) PITTSBURGH – UPMC has implanted the first patient in the U.S. with a new wireless retinal device as part of a clinical trial aimed at restoring partial sight to patients with advanced age-related macular degeneration.

“Vision research has advanced dramatically in the recent past and UPMC is at the forefront of this revolution. This is the first of many such breakthroughs led by UPMC and Pitt that will benefit patients with vision loss in our community and around the world,” said José-Alain Sahel, MD, director of the UPMC Eye Center, Eye and Ear Foundation chair of ophthalmology and distinguished professor at the University of Pittsburgh School of Medicine who initiated the trial at UPMC. “We are proud to be the first center in the United States to test this next generation retinal implant that could help treat an incurable disease like AMD.”

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

The system, called PRIMA, is designed to restore sight in patients blinded by retinal degeneration. It consists of a 2 millimeter-by-2 millimeter, 30-micron thick miniaturized wireless photovoltaic chip placed under the damaged retina. It works in tandem with augmented reality glasses that have a built-in miniaturized camera and infrared projector.

The chip acts like a tiny artificial retina, made up of 378 tiny electrodes that convert infrared light from the glasses to electrical signals that are carried by the optic nerve to the brain. After receiving the implant, patients undergo an intensive rehabilitation program that trains their brains to understand and interpret the signals from the implant in combination with their remaining natural vision. Compared to earlier-generation implants, PRIMA is wireless and has significantly more electrodes, which allows for the transmission of more visual information.

“This is an incredibly exciting first for us at UPMC and I’m honored to be a part of it,” said Joseph Martel, MD, the implanting surgeon at the UPMC Eye Center and the Pitt School of Medicine, and the principal investigator of the trial at UPMC. “I’m grateful to our patients who have volunteered to participate in this trial, without whom this would not be possible.”

AMD is the leading cause of vision loss in people older than 50. Today, it affects approximately 14 million people in the United States, and the prevalence is expected to rise as the baby boomers age. As AMD progresses, the center of vision becomes increasingly blurry. “Atrophic” AMD, which accounts for a large proportion of advanced cases, has no curative treatment available.

The UPMC feasibility trial is running in parallel with the first-in-human trial in France, which involves five patients with advanced AMD, who now have been followed for more than a year. The 12-month results from the French study demonstrated the ability of most patients to identify sequences of letters and there were no device-related serious adverse effects.

“We are working with a great sense of urgency because the aging population of the United States, especially the western Pennsylvania region we live in, will see a significant rise in the number of patients at risk for vision loss through diseases like age-related macular degeneration, glaucoma and vascular eye disease, as well as earlier onset genetic conditions such as retinitis pigmentosa,” said Sahel. “This is why our physicians and researchers at UPMC and Pitt, in collaboration with our U.S. and international colleagues — especially at the Paris Vision Institute at Sorbonne University — are taking a multi-pronged effort to treat and rehabilitate patients with vision impairments.”

In March 2019, UPMC broke ground on the UPMC Vision and Rehabilitation Tower at UPMC Mercy, which when completed, will provide advanced specialty clinical care and innovative programs for visually impaired patients. It also will be the home for the vision research program at Pitt and UPMC.

The PRIMA implant was invented by Daniel Palanker, professor of ophthalmology at Stanford University, and licensed and developed by Pixium Vision, a spin-off from the Paris Vision Institute. Sahel is a co-founder of Pixium and holds shares in the company.

Continue Reading

Advertisement

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Facebook

Most Popular